Pulmosaic

Private beta for clinicians. Free for clinicians.

Lung disease cases, worked through with the evidence in view.

Evidence-linked decision support and case-based teaching for interstitial lung disease and airway disease, built for community clinicians.

Request access See example cases

IPF case next steps with guideline citations
Pulmosaic ILD briefing: most consistent with idiopathic pulmonary fibrosis, well supported, with the reasoning and differential

See it in action

Four example cases, start to finish

Each pair of screens below comes from the same synthetic case, in the order a clinician would see it.

COPD

COPD, frequent exacerbations, eosinophils 400

Post-bronchodilator FEV1 38% predicted, two steroid bursts and one hospitalization in the past year on ICS-LABA.

COPD case assessment: GOLD 3, group E, eosinophilic phenotype
Assessment. GOLD grade and group, the proposed multidimensional COPD schema, and what would change this.
Same COPD case: Nucala and Dupixent as possible fits after triple therapy, with label details
Biologic options. Nucala and Dupixent, flagged as considered after triple therapy, with label dosing and citations.

Severe asthma

Severe eosinophilic asthma, uncontrolled

High-dose ICS-LABA with two oral steroid bursts in the past year, blood eosinophils 420, FeNO 48.

Severe asthma case assessment: uncontrolled, high exacerbation risk, type 2 high
Assessment. Control, exacerbation risk, and type 2 markers, with what would change this.
Same asthma case: biologic options ranked by fit with label doses
Biologic fit. Each biologic matched to its label and pivotal trial population, with doses and sources.

IPF

Idiopathic pulmonary fibrosis with progression

UIP pattern with honeycombing and traction bronchiectasis, lower-lung predominant, with physiologic decline.

IPF case briefing: well supported, with the differential and also-consider list
Briefing. Well supported, with the reasons shown and an "also consider" list naming the test or history that would sort each one out.
Same IPF case: treatment options, follow-up and monitoring with guideline citations
Next steps. Treatment options, follow-up and monitoring intervals, and comorbidity review, each with its guideline source.

Hypersensitivity pneumonitis

Fibrotic hypersensitivity pneumonitis, mold exposure

Mold or water damage at home with mosaic attenuation on CT; serology and BAL not yet recorded.

HP case briefing: partly supported, with what would change this
Briefing. Partly supported, with the specific findings that would make the diagnosis more confident.
Same HP case: next steps, referral, and case-based teaching
Next steps. Monitoring, supportive care, a nearby ILD center, a referral summary, and a teaching request.

Beyond the briefing

Teaching, rare disease, and expert centers

Case-based teaching questions
Case-based teaching. Modeled on Project ECHO. A thoracic radiologist and an ILD educator answer with a teaching point, cited evidence, and what would change it. Education, not a consult.
LAM case briefing with the cystic lung disease differential
Rare disease. LAM, BHD, PLCH, PAP, and other uncommon ILDs, with the confirmatory tests each one needs.
Nearest Pulmonary Fibrosis Foundation care centers to a ZIP code
Find an expert center. PFF care centers by ZIP code, plus LAM, sarcoidosis, and PAP networks matched to the likely diagnosis.

How it works

  1. Enter the case once

    Structured questions in plain clinical language.

  2. Get an evidence-linked briefing

    The reasoning, the gaps, and the sources behind each point.

  3. Request teaching

    Bring the de-identified case to educators when you want a deeper discussion.

Built for clinical data

Contact

Questions or interested in the private beta?

chase@ameforesight.com